Progress in understanding the abnormal regulation of hematopoiesis in chronic myelogenous leukemia (CML) would be facilitated if neoplastic cells, at all stages of the disease, could be studied in an animal model. In this report, we show that irradiated severe combined immunodeficient (SCID) mice can be transplanted with both normal (Philadelphia chromosome [Phl-negative) and neoplastic (Ph') cells from CML patients with either chronic or blast phase disease. Mice transplanted with peripheral blood (PB) or bone marrow (BM) cells from 9 of 12 chronic phase CML patients were well engrafted with human cells including multilineage colony-forming progenitors and CD34+ cells for at least 90 days posttransplantation. Repeated posttransplant injections of cytokines did not enhance the number of engrafted human cells. Interestingly, approximately 70% of the human progenitors found in the engrafted SClD BM were Ph-, suggesting that the growth of primitive normal cells is favored
HRONIC MYELOID LEUKEMIA (CML) is thought
to arise in a pluripotent hematopoietic stem cell that has undergone a reciprocal translocation between the bcr locus on chromosome 22 and the ab1 proto-oncogene on chromosome 9 .l. ' This results in the creation of a shortened chromosome 22, first identified in 1960 and designated as the Philadelphia (Ph) chrom~some.~ Although CML involves the amplification of a clone that produces all blood cell lineages (and their progenitors), at the level of mature cells, only granulocytes and platelets are typically elevated. The chronic phase of CML lasts on average 4 to 6 years and is then invariably followed by a blastic phase that resembles acute leukemia. Blast transformation is believed to result from the acquisition of additional mutations by Ph+ stem cells or their lineage-committed myeloid or B-lineage progeny. Typical genetic alterations characteristic of blast crisis cells include duplication of the Ph chromosome, the presence of an isochromosome 17q (affecting the p53 gene), and trisomy of chromosomes 8, 19, or 21. 4 Much of our understanding of the biological changes that underlie the development of chronic phase CML has come from studies of committed and multipotent hematopoietic clonogenic progenitors (colony-forming cells [CFCs]) detected by in vitro colony assay^.^ More recently, additional key information has been provided by studies of a more primitive hematopoietic cell type referred to as a long-term culture-initiating cell (LTC-IC). LTC-ICs are defined by their unique ability to generate CFCs for a minimum of 5 weeks on competent fibroblast feeder
In chronic phase CML, the bone marrow (BM) contains normal and Ph+ LTC-ICs, both at reduced frequencies by comparison with that of normal BM, regardless of the white blood cell (WBC) count. In contrast, the average LTC-IC content (similar to the CFC content) of the peripheral blood (PB) of CML patients increases exponentially with the W C count (up to levels > lo5 times the LTC-IC concentration in normal PB), and these circulating LTC-ICs and CFCs are predominantly Ph+.8.9 Therefore, expansion of the mature myeloid compartment in CML is a likely consequence of an expansion in extramedullary sites of neoplastic cells corresponding to the earliest stage of normal hematopoiesis. Recent findings suggest that the expansion may occur as a result of an inability of primitive neoplastic cells to respond to certain negative regulators that maybe normally operative within the marrow microenvironment." The mechanism responsible for the enhanced exit of primitive Ph+ cells from the BM is not known but may be related to defects in their adhesion properties." Because Ph+ LTC-ICs disappear rapidly in vitro, even when cultured under conditions optimized for the support of nor-mal LTC-ICs,' it has been difficult to investigate how such LTC-ICs might lead to a granulocytosis in vivo.
The ability of human hematopoietic cells to repopulate irradiated immunodeficient mice has provided a powerful approach to the development of in vivo assays for transplantable normal and leukemic Our recent studies have characterized a severe combined immunodeficient (SCID)-repopulating cell (SRC) present in normal adult BM or cord These transplantable cells can maintain a multilineage population of human hematopoietic cells in the BM of injected SCID mice for at least 4 r n~n t h s . '~. '~ Using similar transplantation procedures, we have identified SCID-leukemia initiating cells from acute myelogenous leukemia patients that rapidly engraft SCID mice and proliferate to high levels in response to in vivo cytokine stimulation.'' These findings suggested that the SCID model might offer a unique opportunity to develop a functional in vivo assay for the transplantable leukemic stem cells known from previous human studies to be present in CML patients, although attempts by several laboratories to transplant chronic phase CML cells into SCID mice by various routes of injection had not been successful.'"'' Even blast crisis CML cells, when transplanted by intraperitoneal injection or by injection under the renal capsule, had low to moderate growth with a slow rate of dissemination of the leukemic blasts to the murine BM (typically requiring 3 to 6 months).'"'' An alternative model for growing leukemic CML cells relies on the use of fetal human bone fragments implanted subcutaneously into SCID mice. Cells from a blast crisis CML, injected into such a bone fragment, grew locally but failed to disseminate to the murine BM.~"
In this study, we describe the consistent engraftment of SCID BM by human hematopoietic cells after the transplantation of a large inoculum of cells from patients with either chronic or blast phase CML using protocols similar to those we have used previously to transplant normal human BM" or human acute myelogenous leukemia" cells. In addition to showing multilineage engraftment, we found that cells with an immature phenotype (CD347 were maintained in the mice for long periods of time. The presence of the Ph chromosome in a proportion of the human CFCs isolated from the BM of these mice was inferred from the detection by reverse transcription-polymerase chain reaction (RT-PCR) of bcr-nbl transcripts in their clonal progeny or by direct cytogenetic analysis. Cells from CML patients in blast crisis (either myeloid or lymphoid) engrafted SCID mice more rapidly than chronic phase cells. In addition, these cells gave rise to exclusively Ph+ progenitors in transplanted mice.
MATERIALS AND METHODS
Donor samples. BM and PB samples were obtained from patients with informed consent according to procedures approved by the Human Experimentation Committee at the Princess Margaret Hospital (Toronto, Canada), The Toronto Hospital, and The Vancouver Health Sciences Hospital (Vancouver, British Columbia).
All chronic phase CML patients were newly diagnosed and had a PB count of over 40 X lo9&. Fresh PB was diluted 1:2 in Iscove's modified Dulbecco's medium (IMDM) containing 10% fetal bovine serum and enriched for mononuclear cells by Ficoll density gradient centrifugation. A total of 8 to 14 X lo7 of these light density cells were injected into the tail vein of sublethally irradiated (400 cGy using a 137Cs y-irradiator) SCID mice, unless otherwise stated. In vivo cytokine stimulation was performed by injecting mice intraperitoneally with PIXY321 (7 pg) and mast cell growth factor (c-kit ligand; 10 pg) on alternate days. Mice were killed 30 to 90 days after transplantation. C.B. 17/scidlscid (SCID) mice were bred and maintained in the defined flora animal colony at the Ontario Cancer Institute (Toronto, Canada).
Cell preparation. Mice were killed at varying intervals after the transplantation of CML PB or BM. The contents of 2 femurs and 2 tibias were suspended in IMDM plus 10% fetal calf serum (FCS). Cells from some mice were then shipped on wet ice by overnight courier to Vancouver.
Assessment of the human cell content oj'mouse BM. The proportion of human cells in recipient mouse BM suspensions was quantified by Southern blot analysis using a human-specific probe as previously d e~c r i b e d , '~,~' or by flow cytometry using a FACScan (Becton-Dickinson, San Jose, CA) analyzer. For some samples, Southern analysis was performed to detect the rearranged bcr gene using a Bgl IIIHindIII probe that contains the human bcr exon Cells were sorted using a FACStar Plus (Becton Dickinson) equipped with a 5 W argon and a 30 mW helium neon laser. Specific fluorescence of FITC and PI excited at 488 nm (0.4 W) and 633 nm (30 mW) as well as forward and orthogonal light scatter signals were used to define sort windows. Cells were defined as positive for gate settings that excluded 99.5% of the cells in negative controls.
Hematopoietic progenitor assays. Plating conditions selective for colony formation by human progenitors (and that do not support coexisting mouse progenitors) have been described elsewhere.*' Briefly, 2 x IO5 BM cells obtained directly from transplanted mice were plated in 0.9% methylcellulose containing fetal bovine serum (15%), human plasma (15%), human mast cell growth factor (50 ng/ mL), PIXY321 (5 ng/mL), human granulocyte-macrophage colony- stimulating factor (CSF I UlmL), human interleukin-3 (IL-3; 10 U/ mL), erythropoietin (2 UlmL) and P-mercaptoethanol (IO-' mol/L).
For sorted CD34' cells, progenitors were assayed at 8400 cells/ mL in standard 0.8% methylcellulose cultures containing 30% FCS, 1% bovine serum albumin, IO-' mol/L 8-mercaptoethanol, and IMDM (StemCell Technologies [STI] . Vancouver, British Columbia) supplemented with 3 UlmL human erythropoietin (Stem Cell Technologies), 50 nglmL stem cell factor (SCF Amgen, Thousand Oaks, CA), and 20 ng/mL each of IL-3, granulocyte-macrophage CSF (Sandoz, Basel, Switzerland), granulocyte CSF (Amgen), and IL-6 (obtained from the supernatant of COS cells transfected with a full-length copy of the human IL-6 cDNA).
RT-PCR ona/wis. RT-PCR was performed following a modified protocol of Kawasaki." Briefly, individual colonies were picked and washed in 50 pL of RNase-free phosphate-buffered saline. Cells were resuspended in 4 pL of IHB buffer (140 mmol/L NaCI; 10 mmol/L Tris-HCI, pH 8; 1 .S mmol/L MgC12) containing fresh NP40 (0.5%) and 10 pUmL of a 10% diethyl pyrocarbonate (DEPC) solution dissolved in ethanol. Cells were vortexed vigorously and incu- 
kb-",
bated at 37°C for 20 minutes. This was followed by a 20-minute incubation at 90°C to allow for evaporation of the DEPC. Cells were then centrifuged, kept on ice and S pL of RT master mix (IOX RT buffer: 500 mmol/L Tris-HCI, pH 8.3: 30 mmoln MgCI?; 400 mmoll L KCI: 0.2 mmol/L each of the four deoxynucleotide triphosphates [dNTPs]; 1 0 0 ng of oligo RT-ob/) was added. Formation of secondary mRNA structures was prevented by incubating lysed cells for I minute at 65°C and then for 3 minutes at room temperature to allow annealing of the oligos. The sample was then centrifuged and placed on ice before adding l pL of a I : I mixture of avian myeloblastosis virus (AMV; Boehringer Mannheim. Quebec, Canada):Moloney murine leukemia virus (MoMuLV: Boehringer Mannheim) reverse transcriptase. The reaction was performed at 37°C for I hour, after which the tubes were placed on ice. Samples could be frozen at this stage.
Nested PCR was performed by incubating half (ie, S pL) of the RT reaction mixture with 4.5 pL of preheated (80°C) master mix containing oligos hcr-l and o h / -/ . After the first round of amplification. S pL of this mixture was incubated with 45 pL of a master mix containing the oligos bcr-2 and ob/-2, which are internal to the first set of oligos, and was subjected to a second round of amplilication. An internal control was provided by incubating the remaining S pL of the RT reaction mixture with 45 pL of preheated (80°C) master mix containing the oligos it?t-nhl-l and RT-nhl. These oligos amplify oh/ sequences 3' to the site of translocation in both Ph-and Ph' human cells. PCR was performed as follows: an initial denaturing step at 94°C for 7 minutes followed by 35 cycles of IS seconds at 94°C. IS seconds at S S T , and 30 seconds at 72°C and then a final incubation step at 72°C for 7 minutes. All oligos were used at a concentration of 100 ng per reaction. The sequences of the oligos used are as follows: bcr-l. S'-AGC ATG GCC TTC AGG GTG CAC AGC CGC AAC GGC AA-3'; ah/-l, S'-TCA CTG GGT CCA GCG AGA AGG TTT TCC TTG GAG TT-3': bcr-2. S'-GTT CCT GAT CTC CTC TGA CTA TGA GCG TGC A-3': ~h / -2 , S"TCA GAC CCT GAG GCT CAA ACT C-3'; ittt-<//d-l. S'-CAG CGG CCA GTA GCA TCT GAC TT-3'; and RT-dd, S'-CTC CAC TGG CTrogcrzctic ana/ysis. After 10 to 14 days of incubation. methylcellulose plates containing colonies were treated with 100 pL of colcimid (10 pglmL) and then incubated for an additional 16 hours. Colonies were picked and processed individually or in small pools, and G-banded chromosomes were obtained by staining the chromosome spreads with Giemsa according to established procedures."
CCA CAA AAT-3'.
RESULTS
Cells from CML patients in chronic phase repoprlcrte tire BM qfSClD mice. Cells obtained from 12 newly diagnosed chronic phase CML patients were transplanted by intravenous injection into sublethally irradiated SCID mice. After 30 to 60 days, the extent of human engraftment in the BM of most of these mice was measured by Southern analysis using a human-specific DNA probe. The results of an experiment that shows good engraftment using the Southern tech- In this sample, = 15% of the viable (PI-) from 6 patients: see Fig IB, insert) . cells were of human origin, as indicated by positive CD45 Cells from several highly engrafted mice were also anastaining (Fig 2A) . This cell population was then subdivided lyzed 30 to 50 days after transplantation by flow cytometry into "myeloid" (R2) and "lymphoid" (R3) components using monoclonal antibodies specific for different human according to the forward and side scatter properties charachematopoietic cell lineages. The results from a representative teristic of mature human myeloid and lymphoid cells ( ( Fig 2C) , which is in agreement with morphological analyses (data not shown). Most (95%) of the CD45' lymphoid cells were CD19', indicative of their differentiation into B-lineage cells (Fig 2D) . In fact, these cells comprised 12% of the total human cell population in this case. Similar results were obtained in 3 other mice, 2 of which were transplanted with cells from donor sample no. 16 (data not shown).
To assess whether more primitive human hematopoietic cells were also present in the transplanted mice, BM cells from 52 mice were also stained with an antihuman CD34 antibody; an example is shown in Fig 3A. Sixty days after transplantation, 1.1% of the viable cells in this recipient's BM were CD34+. The total numbers of CD34' cells detected in the four bones (2 tibiae and 2 femurs) of each of the 23 engrafted mice is shown in Fig 3B. The mean number of CD34' cells per four bones in mice in which CD34+ cells were detected was 2.9 X lo4 (ranging from 1.6 X lo3 to 1.5 X lo6 cells). The BM of the 29 other transplanted mice analyzed did not contain any detectable CD34+ cells (data not shown). Most of these latter mice also had no detectable human cells when analyzed by Southern blotting or colony assays. Interestingly, CD34+ cells were present at comparable levels in mice transplanted with either BM or PB cells (Fig 3B) .
To determine if human CFCs could be detected in the transplanted mice, either unseparated BM cells were plated directly in methylcellulose under conditions that are selective for human CFCs, or selected CD34' cells (and hence free of murine cells) were plated under standard conditions optimized for human CFCs. Results from over 80 mice transplanted with cells from 12 patients are shown in Fig 4. Similar to the variability observed in the human DNA content of these mice (Fig lB) , the results of the CFC assays showed considerable heterogeneity in the number of human CFCs present in mice transplanted with cells from the same donor sample. As many as 20,000 human CFCs could be found in four bones (2 tibias and 2 femurs) of 1 recipient 50 days posttransplant, although the mean CFC content (260) was considerably lower (Fig 4) . All mice that showed high levels of human cell engraftment also contained multiple lineages of CFCs including granulocyte, erythroid, monocyte, megakaryocyte colony-forming unit; erythroid burstforming unit; and granulocyte-macrophage colony-forming unit.
Because of the low BM cellularity in some of the transplanted mice, only assays for human CFCs, instead of Southem analysis, were performed on this subset of recipients. Particularly high numbers of CFCs were detected in the BM of mice transplanted with cells from donor sample no. 16 and occasionally from other samples (Fig 4) . These results, in combination with those shown in Fig 1, provide evidence of human hematopoietic cell engraftment in SCID mice injected with cells from 9 of the 12 newly diagnosed patients for whom samples were obtained and tested.
Mixed genotypes present in SCID mice transplanted with chronic phase cells. Because normal stem cells coexist with the leukemic clone in CML patients: ' it was important to determine the genotype of the human cells present in the SCID mice. This was accomplished primarily by performing RT-PCR analysis on colonies generated in assays of recipient BM cell suspensions to identify the presence of bcr-ab1 transcripts. A representative RT-PCR is shown in Fig 5A. Thirty days after transplantation, 5 of the 20 picked colonies shown in this experiment contained bcr-ab1 transcripts. A total of 297 colonies generated in assays of BM cells from recipients of BM or PB from 8 CML patients were analyzed in this way. Of these, 32% ? 10% were positive for bcr-ab1 expression (Table 1) . Because the failure to detect bcr-ab1 transcripts may not necessarily correlate with the absence of the Ph c h r o m~s o m e ,~~.~~ a number of colonies (278) were also analyzed cytogenetically (Fig SB) . Although all were found to be human, the presence of the Ph chromosome was also limited to a small proportion of these (13% -+ 4%; see Table  1 ). These results clearly indicate that a mixture of normal Evidence of the presence of normal human as well as leukemic cells in the engrafted mice was also obtained from Southern blot analyses that showed the intensity of the rearranged bcr gene where present to be consistently weaker than the intensity of the hcr germ-line band (data not shown). In addition, these analyses confirmed that the proportion of normal human cells present did not differ between recipients of PB or BM from the same donor ( Table l ) .
Engrqftment of leukemic cells in SCID recipients of cells from CML patients in blast crisis. To determine the kinetics of engraftment and the extent of chimerism obtained with cells from CML patients in blast crisis, 1 to 4 X IO7 cells from 3 myeloid and 1 lymphoid blast crisis patients were transplanted into irradiated SCID mice. Between 22 and 45 days later, mice were killed, and the proportion of human cells present was determined by Southern blot analysis, flow cytometry, and/or examination of BM touch preparations. Cells from all 4 blast crisis donors engrafted the mice at high levels. The BM of 8 0 8 of the mice contained at least 10% human cells (Table 2) , and these included multiple lineages of CFCs (mostly CFU-GM and BFU-E). As expected, all of the 31 metaphases analyzed from these latter colonies contained the Ph chromosome (Table 2 ). In addition. in 2 experiments. blast colonies, such as those obtained in routine assays of cells from AML patients, were observed in the colony assays of BM cells obtained from mice transplanted with blast crisis cells. These results show that SClD mice can be repopulated with human hematopoietic cells with different properties according to their origin from CML patients with chronic as compared with blast phase disease.
Flow cytometric analysis of the BM of mice transplanted with cells from donor sample no. 24, which was a CML patient in lymphoid blast crisis, indicated that 93% of the cells were of human origin (Fig 6) . These cells had a cell surface phenotype that was similar to the dominant blast phenotype of the cell population originally transplanted. ie, high levels of CD34, CD19, and HLA-DR, and low levels of CD45 (Fig 6) . Thirty to ninety days posttransplant, B M cells isolated from SClD mice were plated directly (or after selection of CD34' human cells) in methylcellulose cultures. Single colonies were picked 10 to 14 days after incubation and analyzed for the presence of either bcr-ab/ transcripts using RT-PCR or the Ph chromosome by cytogenetics as described in the Materials and Methods.
Abbreviation: PBL, PB leukocyte.
* Metaphases from single and pooled colonies were examined. At least two informative metaphases were analyzed per colony or pool.
t Colonies were derived from sorted CD34' cells. t Colonies were scored after 14 days of incubation at 37°C. Colonies of cells classified as "leukemic" are those that showed a distinct blast appearance and in some cases confirmed by microscopic analysis of plucked cells.
* RT-PCR and metaphase analyses were performed on individual colonies derived from erythroid burst-forming units and granulocytemacrophage colony-forming units as indicated in Table 1 .
DISCUSSION
This study provides the first evidence that both normal and leukemic hematopoietic cells present in CML patients in chronic phase can engraft the BM of sublethally irradiated SCID mice. Samples from 9 of 12 newly diagnosed patients gave a high proportion of human cells in the BM of SCID mice 1 to 3 months posttransplant; samples from the 5 other patients also engrafted but at lower levels. It should be noted that the number of chronic phase CML BM cells injected was twofold to fourfold higher than that previously found to give a similar level of engraftment when normal BM cells were transplanted (2 to 6 X IO7 light density cells per m o~s e ) . '~ With lower doses of CML cells, very low levels of human cell engraftment was detectable in 6 of 6 experiments. Increasing the number of CML cells injected to greater than 8 X IO7 resulted in consistent, but still variable, levels of engraftment with samples from all 12 CML chronic phase patients. Interestingly, the level of engraftment was not affected by exogenous treatment with human cytokines, in contrast to previous findings with transplants of normal human BM.'4 It is possible that the leukemic cells can secrete cytokines that support the engraftment of both leukemic and normal cells. We have previously shown that expression of bcr-abl can induce the secretion of cytokines in human myeloid cell lines,** although searches for the constitutive activation of cytokine production in primary CML cells have, to date, proven negative.29 More detailed characterization of human cells present in the BM of highly engrafted mice indicated the presence, for at least 90 days, of multiple lineages of human cells, including CD13+ myeloid cells and CD19' B-lymphoid cells as well as more primitive cells identified phenotypically by their expression of CD34 andl or functionally by their in vitro colony-forming capacity. Because mature myeloid cells have a very short lifespan (1 to 2 days), these results suggest a continuous proliferation and differentiation of these earlier types of human precursors into more mature progeny within the BM microenvironment of the SCID host. The growth of CML cells was largely restricted to the BM, the spleen and liver were not enlarged, and expanded numbers of neutrophils were not seen in the PB .
Both molecular and cytogenetic analyses indicated that mice transplanted with chronic phase CML cells were repopulated typically with normal (Ph-) as well as leukemic (Ph') cells. In fact, in all cases, normal cells made up the majority of the human hematopoietic cells present. Interestingly, a similar predominance of normal hematopoiesis was observed when PB cells from the same patients were transplanted, indicating that normal SRC are present in CML PB as well as BM. This latter result was not anticipated from the in vitro data available at the time these studies were initiated, which indicated that only leukemic CFCs and LTC-ICs are present at greatly increased concentrations in the PB of CML patients with elevated WBC counts.x.'."' However, more recently we have found that high numbers of normal LTC-ICs are also mobilized into the PB of such patients." These results establish that the BM and PB of CML patients in chronic phase do contain normal and Ph' SRC that are capable of sustaining normal and leukemic hematopoiesis, respectively, in SCID mice. More extensive analysis will need to be performed to determine the frequency and characteristics of these normal and Ph' SRC and to compare them with normal and Ph' LTC-ICs as well as with related cell types in normal individuals.
The prevalence of normal cells detected in the transplanted SCID mice could be influenced by features intrinsic to the Ph' stem cells transplanted andor to the SCID system. For example, primitive Ph' cells may be more sensitive to natural killer (NK) activity than their normal counterparts.32.33 Although SCID mice lack B and T cells, they do produce NK cells that are f~n c t i o n a l .~~ Therefore, SCID mice might preferentially repress the transplanted leukemic cells or their progeny. More recently, we have found that the NOD/SCID mouse, which shows defective NK activity, may allow superior engraftment of human cells with smaller transplants of normal or leukemic human cells.'s.3s.36 Alterations in the adhesion properties of immature CML progenitors'' might also contribute to a selective reduction in their homing or growth in SCID mice.
The availability of a SCID-CML model provides new opportunities for future studies of the biology of CML as well as for evaluating therapeutic strategies. A clinically important feature of CML is its invariable progression to a blast crisis phase. Although the emergence of the Ph chromosome at the onset of the disease implicates bcr-ab1 as an early transforming event leading to clonal amplification, the onset of blast crisis is generally associated with the appearance of a subclone of Ph' cells carrying one or more additional genetic alterations. In this study, we have shown that cells from the PB of blast crisis CML patients can readily repopulate the BM of sublethally irradiated SCID mice with cells that show the same functional, genetic (Ph'), and morphological features of the original cells transplanted. Therefore, the SCID mouse system should also be useful for investigation of the time course and mechanisms of leukemic progression in human CML.
